The safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in ...

Enhertu is a HER2-directed antibody drug conjugate (ADC) that has already shown improved outcomes in six Phase III breast cancer trials across different subtypes and stages of disease.

Enhertu was first approved by the FDA in 2019 as a third-line treatment for HER2-positive metastatic breast cancer. The therapy expanded its approved use to second-line treatment of this type ...

TOKYO & BASKING RIDGE, N.J., April 21, 2025--ENHERTU Combination Demonstrated Statistically Significant Improvement in PFS vs. THP as First-Line Therapy in HER2 Positive Metastatic Breast Cancer ...

First-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) plus Perjeta (pertuzumab) demonstrated highly statistically significant and clinically meaningful improvement in progression-free ...

Enhertu is the primary driver of Daiichi’s revenue. For fiscal year 2024, Enhertu forecast is ¥539.9 billion (~$3.50 billion) in global revenue, up from ¥449 billion in FY2023 (see page 11, here).

Among patients with human epidermal growth factor receptor 2 (HER2, IHC 3+ or IHC 2+/ISH+) positive unresectable and/or metastatic gastric or gastroesophageal cancer, Enhertu (trastuzumab deruxtecan) ...

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

The Food and Drug Administration (FDA) has approved Enhertu ® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...